Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Su Pin Choo

Showing results (61-70 of 95) with videos related to

Pageof 10
Sort By:
Liver Cancer|September 26, 2022
Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and TaiwanThomas Yau, David Tai, Stephen Lam Chan, et al.
Hepatology International|July 24, 2015
Survival and pattern of tumor progression with yttrium-90 microsphere radioembolization in predominantly hepatitis B Asian patients with hepatocellular carcinomaAndrew Yu-Keat Khor, Ying Toh, John Carson Allen, et al.
Asia-Pacific Journal of Clinical Oncology|November 27, 2024
Impact of Antibiotics and Chronic Medications on Efficacy of Immune Checkpoint Inhibitors in Patients With Hepatocellular CarcinomaKennedy Yao Yi Ng, Albert Eng Keong Teo, Sze Huey Tan, et al.
Plos One|April 2, 2015
The Singapore Liver Cancer Recurrence (SLICER) Score for relapse prediction in patients with surgically resected hepatocellular carcinomaSoo Fan Ang, Elizabeth Shu-Hui Ng, Huihua Li, et al.
Asia-Pacific Journal of Clinical Oncology|November 19, 2019
What is the value of third-line chemotherapy in advanced gastroesophageal cancer? A 5-year retrospective analysis at a single centerJustina Yick Ching Lam, Su Pin Choo, David Wai-Meng Tai, et al.
BMC Cancer|November 9, 2016
Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trialMihir Gandhi, Su Pin Choo, Choon Hua Thng, et al.
Lancet (London, England)|April 25, 2017
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trialAnthony B El-Khoueiry, Bruno Sangro, Thomas Yau, et al.
NPJ Precision Oncology|November 13, 2025
High clinical actionability of a pan-cancer tissue-based combined DNA and RNA next generation sequencing assay in a diverse Asian populationJing Yi Lee, Aya El Helali, Donavan Jia Jie Tan, et al.
Surgery|January 8, 2018
Prospective study to determine early hypertrophy of the contra-lateral liver lobe after unilobar, Yttrium-90, selective internal radiation therapy in patients with hepatocellular carcinomaJin Yao Teo, John Carson Allen, David Chee Eng Ng, et al.
JAMA Oncology|July 18, 2017
Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical TrialYoon-Sim Yap, Li-Lian Kwok, Nicholas Syn, et al.
Pageof 10

Showing results (61-70 of 95) with videos related to

Sort By:
Pageof 10
Liver Cancer|September 26, 2022
Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and TaiwanThomas Yau, David Tai, Stephen Lam Chan, et al.
Hepatology International|July 24, 2015
Survival and pattern of tumor progression with yttrium-90 microsphere radioembolization in predominantly hepatitis B Asian patients with hepatocellular carcinomaAndrew Yu-Keat Khor, Ying Toh, John Carson Allen, et al.
Asia-Pacific Journal of Clinical Oncology|November 27, 2024
Impact of Antibiotics and Chronic Medications on Efficacy of Immune Checkpoint Inhibitors in Patients With Hepatocellular CarcinomaKennedy Yao Yi Ng, Albert Eng Keong Teo, Sze Huey Tan, et al.
Plos One|April 2, 2015
The Singapore Liver Cancer Recurrence (SLICER) Score for relapse prediction in patients with surgically resected hepatocellular carcinomaSoo Fan Ang, Elizabeth Shu-Hui Ng, Huihua Li, et al.
Asia-Pacific Journal of Clinical Oncology|November 19, 2019
What is the value of third-line chemotherapy in advanced gastroesophageal cancer? A 5-year retrospective analysis at a single centerJustina Yick Ching Lam, Su Pin Choo, David Wai-Meng Tai, et al.
BMC Cancer|November 9, 2016
Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trialMihir Gandhi, Su Pin Choo, Choon Hua Thng, et al.
Lancet (London, England)|April 25, 2017
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trialAnthony B El-Khoueiry, Bruno Sangro, Thomas Yau, et al.
NPJ Precision Oncology|November 13, 2025
High clinical actionability of a pan-cancer tissue-based combined DNA and RNA next generation sequencing assay in a diverse Asian populationJing Yi Lee, Aya El Helali, Donavan Jia Jie Tan, et al.
Surgery|January 8, 2018
Prospective study to determine early hypertrophy of the contra-lateral liver lobe after unilobar, Yttrium-90, selective internal radiation therapy in patients with hepatocellular carcinomaJin Yao Teo, John Carson Allen, David Chee Eng Ng, et al.
JAMA Oncology|July 18, 2017
Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical TrialYoon-Sim Yap, Li-Lian Kwok, Nicholas Syn, et al.
Pageof 10